Stock Screener App

Frei -

Installieren

4.28

4.04% -0.18

Onkure Therapeutics Inc (OKUR)

Überblick Nachrichten Preisverlauf Forum Prognose

Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten

ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView

Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times

OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan

OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com

OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Completeness Index - marketscreener.com

OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com

OnKure Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:OKUR) - TradingView

OKUR Forecast — Price Target — Prediction for 2027 - TradingView

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC) - The Globe and Mail

OnKure Therapeutics president and CEO sells $378 in stock By Investing.com - Investing.com Nigeria

OnKure Therapeutics president and CEO sells $378 in stock - Investing.com

OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock - Investing.com

Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria

OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock By Investing.com - Investing.com Nigeria

[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity - Stock Titan

OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding - Stock Titan

Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey

Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Onkure Therapeutics Inc (OKUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

OKUR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com

Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey

OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com

OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com

OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Edges HigherWeak Earnings Momentum - dars.gov.et

OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan

OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan

Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan

OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan

OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan

OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan

Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com

OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail

OnKure Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo

OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan

OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com

OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com

OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate

OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com

[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate

OKUROnKure Therapeutics Inc Stock Price and Quote - Finviz

OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate

Survey finds most Boulder residents satisfied with quality of life - BizWest

OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser

OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser

OnKure Therapeutics (OKUR) Jumps +7.88% on Strong Momentum 2026-05-20Technical Analysis Picks - The Legal Advocate

ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan

TradingKey - TradingKey

The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters